Journal of Maternal-Fetal and Neonatal Medicine (J MATERN-FETAL NEO M)

Publisher: European Association of Perinatal Medicine; Federation of Asia and Oceania Perinatal Societies; International Society of Perinatal Obstetricians, Informa Healthcare

Journal description

The official journal of The European Association of Perinatal Medicine, The Federation of Asia and Oceania Perinatal Societies, and The International Society of Perinatal Obstetricians.

Current impact factor: 1.21

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 1.208
2012 Impact Factor 1.518
2011 Impact Factor 1.495
2010 Impact Factor 2.071
2009 Impact Factor 1.362
2008 Impact Factor 1.089
2007 Impact Factor 1

Impact factor over time

Impact factor
Year

Additional details

5-year impact 1.69
Cited half-life 3.80
Immediacy index 0.20
Eigenfactor 0.01
Article influence 0.45
Other titles Journal of maternal-fetal & neonatal medicine (Online), Journal of maternal-fetal and neonatal medicine
ISSN 1476-7058
OCLC 49941200
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Informa Healthcare

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • On author's personal website or institution website
    • Publisher copyright and source must be acknowledged
    • On a non-profit server
    • Must link to publisher version
    • Publisher's version/PDF cannot be used
    • NIH funded authors may post articles to PubMed Central for release 12 months after publication
    • Wellcome Trust authors may deposit in Europe PMC after 6 months
  • Classification
    ​ yellow

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: The Task Force Study on Neonatal Encephalopathy Second Edition 2014 failed to address Electronic Fetal Monitoring (EFM) and its forty years of clinical futility, failed to condemn EFM’s continued use against physicians in the world’s courtrooms and ignored the ethical breaches EFM’s use compels physicians to commit daily. This article considers why these critical points were overlooked and asks why the Task Force recommended continued EFM use for all women in labor while simultaneously acknowledging EFM’s impotency. This paradox is explored among the background of trial lawyers’ involvement in cerebral palsy and the failure of birthrelated professional organizations to recognize that the Daubert doctrine may be used to exclude EFM junk science from the world’s courtrooms.
    Journal of Maternal-Fetal and Neonatal Medicine 06/2015; early online:1-4. DOI:10.3109/14767058.2015.1051526
  • Journal of Maternal-Fetal and Neonatal Medicine 06/2015; DOI:10.3109/14767058.2015.1049148.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Metabolic bone disease (MBD) is one of the important complications of prematurity. Early and adequate nutritional interventions may reduce the incidence and potential complications of MBD. The present study aimed to evaluate bone metabolism in twins via biochemical parameters and quantitative ultrasound (QUS) and to compare the results between twin pairs. Moreover, twin infants were evaluated in terms of potential risk factors likely to have impact on MBD. Forty-three pairs of twins were included in the study. Serum calcium, phosphorus, magnesium and alkaline phosphatase concentrations were assessed and bone mineral density was measured using QUS (speed of sound, SOS) at postnatal 30 days. Co-twin with the higher birth weight was assigned to Group 1 (n=36) and the other twin was assigned to Group 2 (n=36). Birth weight and head circumference were significantly higher in the infants of Group 1 compared to Group 2. No significant difference was found between the groups in terms of gender, history of resuscitation, length of stay in intensive care unit (ICU) or in the incubator, duration of total parenteral nutrition (TPN), type of nutrition, vitamin D use, biochemical parameters, and the SOS value. The factors likely to affect SOS, including type of pregnancy, maternal drug use, gender of infant, birth weight, head circumference at birth, gestational week, length of stay at the ICU, duration of TPN, type of nutrition, resuscitation, vitamin D use, and levels of calcium, phosphorus, magnesium, and alkaline phosphatase were entered into the model. The phosphorus level and maternal drug use were found to be the factors that significantly reduced SOS, whereas pregnancy after assisted reproductive techniques was found to be a significant enhancing factor.
    Journal of Maternal-Fetal and Neonatal Medicine 03/2015; DOI:10.3109/14767058.2015.1025743
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background/Objective Approximately 10% of small for gestational age (SGA) infants fail to catch up. The relationship between postnatal growth and placental pathology in SGA infants remains unclear. Our aim was to assess the involvement of placental pathology in postnatal growth of SGA infants. Methods We retrospectively evaluated placental pathology and postnatal growth in single-pregnancy infants born after 37 gestational weeks in our institution, with both birth weight and length below -2 standard deviation scores (SDS) of the normal weight and length. 'Catch-up' was defined as height reaching -2 SDS before the second birthday. Pathology of the placenta was classified into: abnormality due to maternal factors or fatal factors, villitis of unknown etiology, other abnormalities, and no abnormality. Results Of 33,084 infants, 142 met our criteria and 49 of them had analyzable data. The overall catch-up rate was 84%. Catch-up growth took place in all infants with no placental abnormality and only 57% of infants with abnormality due to fatal factors. There was no significant relationship between catch-up rate and other factors. Conclusion Placental pathology is associated with postnatal growth in SGA children born at term. Placental abnormality due to fetal factors is related to poor catch-up rate.
    Journal of Maternal-Fetal and Neonatal Medicine 03/2015; DOI:10.3109/14767058.2015.1029911
  • [Show abstract] [Hide abstract]
    ABSTRACT: "What does it mean, Doctor?" and "Is it going to affect my baby in some way?". Those are the most typical questions of pregnant women to obstetricians. Answering is sometimes easier but placental calcification is not the case, since placental architecture and disease are two different faces of the same coin and the association between them is not completely clear. Placenta can function properly, even in the presence of architectural alterations, without any fetal consequences. So, remains the question, when does a placental structural anomaly become a sign of increased attention to maternal conditions, fetal development and wellbeing? The present review will analyze these concepts, with emphasis on placental calcification, its pathogenesis, and the state of the art regarding the influence of this finding on pregnancy outcomes among low-risk pregnant patients.
    Journal of Maternal-Fetal and Neonatal Medicine 03/2015; DOI:10.3109/14767058.2015.1023709
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective Radiography after fetal or perinatal death has become a routine part of post mortem diagnostics. However, only a selected subset of these babygrams or fetal post mortem skeletal surveys (FPSS) provides useful information. We investigated the indication for an FPSS. Methods Inclusion consisted of the routinely made FPSS (2002-2012) in our university hospital in cases of fetal or perinatal death up to 7 days after birth. We categorized the diagnostic value of the FPSS as no, minor, major or pathognomonic. Regression analysis was used to determine the selection criteria for a useful FPSS. Results 337 FPSS were included. 305 (91%) showed no or minor skeletal malformations. 14 (4,2%) FPSS had major skeletal malformations. In 18 (5,3%) cases the diagnosis was based on the pathognomonic skeletal malformations on the FPSS. 2 cases were false positive after major birth trauma. The presence of multiple skeletal malformations on prenatal ultrasound or at post mortem external inspection was highly indicative of a diagnostic FPSS (p<0.001). Conclusion The majority of the babygrams / FPSS has no contribution to the diagnostic process. Multiple skeletal malformations on prenatal ultrasound or post mortem external inspection are indicative for a diagnostic FPSS, and this should be the main selection criterion.
    Journal of Maternal-Fetal and Neonatal Medicine 03/2015; DOI:10.3109/14767058.2015.1029913
  • Journal of Maternal-Fetal and Neonatal Medicine 03/2015; DOI:10.3109/14767058.2015.1020128
  • [Show abstract] [Hide abstract]
    ABSTRACT: verify if small for gestational age preterm newborns (SGA) represent a special risk group for carnitine deficiency. Secondary outcome: assess longitudinal differences of total carnitine (TC), free carnitine (FC) and acylcarnitines between SGA and appropriate (AGA) for gestational age. a retrospective study to evaluate carnitine and acylcarnitines profile on 144 very-low-birth weight newborns (VLBW), classified in AGA (n=73) and SGA (n=71), was performed by tandem mass spectrometry, during their first 5 weeks of life. Carnitine deficiency was defined as FC< 40µmol/L and FC/TC<0.7. carnitine deficiency was observed in the two study groups throughout the monitoring period (maximum FC: 36.05µmol/L in AGA and 32.24µmol/L in SGA). FC/TC remains under 0.7 in both with progressive improvement. Unlike expected, a comparatively higher value of TC, FC and total acylcarnitines (tAC) was found in SGA during the first two weeks, with significant relevance on day third-fifth, specially for tAC (p<0.001). The only acylcarnitine with persistently lower value in SGA is C5 (p<0.05 in first two weeks). a carnitine deficiency was demonstrated in all VLBW. Despite birth weight restriction has been suggested as a risk factor for impaired carnitine status, in our serie, SGA was not related with higher carnitine deficiency.
    Journal of Maternal-Fetal and Neonatal Medicine 03/2015; DOI:10.3109/14767058.2015.1024647
  • [Show abstract] [Hide abstract]
    ABSTRACT: Indomethacin and ibuprofen, are commonly used in the treatment of hemodynamically significant patent ductus arteriosus (hsPDA). These drugs are associated with serious adverse events, including gastrointestinal perforation, renal failure and bleeding. The role of paracetamol has been proposed for the treatment of PDA. We report a series of 11 neonates (Birth weight: 415-1580 g; Gestational age: 23-30.3 weeks) who were treated with paracetamol for a hsPDA. Neonates with hs-PDA were treated with paracetamol in the presence of contraindications to ibuprofen or indomethacin. The condition of significant PDA was defined by the presence of at least one of the following criteria: internal ductal diameter???1.4 mm/kg body weight, left atrium to aortic root ratio?>?1.4, unrestrictive pulsatile transductal flow, reverse or absent diastolic flow in the descending aorta along with clinical findings. Intravenous paracetamol was given at doses 15 mg/kg every 6 hours for three days. Successful ductal closure was achieved in 10 out of 11 babies (90.9%). No adverse or side effects were observed during the treatment. On the basis of these results, paracetamol could be considered a promising and safe therapy for the treatment of PDA in preterm infants.
    Journal of Maternal-Fetal and Neonatal Medicine 03/2015; DOI:10.3109/14767058.2015.1029912
  • [Show abstract] [Hide abstract]
    ABSTRACT: We aimed to determine the effect of a dental support device (DSD) use on the course of labor and delivery in nulliparous women. A randomized, controlled, open-label study of nulliparous (at 37+0/7 and 41+3/7 weeks of gestation) in a single tertiary university-affiliated medical center. Exclusion criteria included maternal chronic diseases, multi-fetal gestation and fetal chromosomal or structural anomalies. Outcomes were analyzed according to the actual use of the DSD, and satisfaction questionnaires following delivery. Overall, 191 women were randomized (93-study and 98 in the control group). The median duration of the second stage was similar between the groups (100.0±91.0 vs. 98.0±128.8 minutes, p=0.97) and the maximal VAS score was significant higher in the DSD group (4.0±8.5 vs. 3.0±6.8, p=0.04). The rate of obstetrical interventions such as operative vaginal delivery or cesarean section during the second stage was significantly higher in the control group than in the study group (28.2% vs. 12.3% and 6.4% vs. 1.2%, respectively, p=0.004), mainly due to prolonged second stage of labor (24.5% vs. 8.6%, p=0.005). Of the DSD group, 50.6% rated the use of the DSD as comfortable, 32.2% rated its effect on pain relief as high, 55.6% would recommend its use to their peers and 51.9% would like to use it in their consecutive delivery. The use of a dental support device among nulliparous women appear to decrease the need for obstetrical intervention due to prolonged second stage of labor, with fair satisfaction of patients.
    Journal of Maternal-Fetal and Neonatal Medicine 03/2015; DOI:10.3109/14767058.2015.1024648
  • [Show abstract] [Hide abstract]
    ABSTRACT: Preterm birth is associated with 5 to 18% of pregnancies and is the leading cause of neonatal morbidity and mortality. Amniotic fluid (AF) interleukin-6 (IL-6) is a key cytokine for the identification of intra-amniotic inflammation, and patients with an elevated amniotic fluid IL-6 are at risk for impending preterm delivery. However, results of the conventional method of measurement (enzyme-linked immunosorbent assay; ELISA) are usually not available in time to inform care. The objective of this study was to determine whether a point of care (POC) test or lateral-flow based immunoassay for measurement of amniotic fluid (AF) IL-6 concentrations can identify patients with intra-amniotic inflammation and/or infection, and those destined to deliver spontaneously before term among women with preterm labor and intact membranes. One hundred thirty six women with singleton pregnancies who presented with symptoms of preterm labor and underwent amniocentesis were included in this study. Amniocentesis was performed at the time of diagnosis of preterm labor. AF Gram stain and AF white blood cell counts were determined. Microbial invasion of the amniotic cavity (MIAC) was defined according to the results of AF culture (aerobic and anaerobic as well as genital mycoplasmas). AF IL-6 concentrations were determined by both lateral flow-based immunoassay and ELISA. The primary outcome was intra-amniotic inflammation, defined as AF ELISA IL-6 > 2,600 pg/ml . 1) AF IL-6 concentrations determined by a POC test have high sensitivity (93%), specificity (91%), and a positive likelihood ratio of 10 for the identification of intra-amniotic inflammation by using a threshold of 745 pg/ml; 2) the POC test and ELISA for IL-6 perform similarly in the identification of MIAC, acute inflammatory lesions of placenta, and patients at risk of impending spontaneous preterm delivery. A point of care AF IL-6 test can identify intra-amniotic inflammation in women who present with preterm labor and intact membranes and those who will subsequently deliver spontaneously before 34 weeks of gestation. Results can be available within 20 minutes-this has important clinical implications and opens avenues for early diagnosis as well as treatment of intra-amniotic inflammation/infection.
    Journal of Maternal-Fetal and Neonatal Medicine 03/2015; DOI:10.3109/14767058.2015.1006620
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine terbutaline success rate in postponing preterm labor for 48 hours and to identify factors associated with its efficacy, side effects, maternal and neonatal outcomes. A retrospective study analyzing data from pregnant women suffering from preterm labor who had received terbutaline for inhibition of labor from January 2007 to December 2013. A total of 385 cases were analyzed; there were 321 cases (83.4%) delivered > 48 hours and 64 cases (16.6%) delivered before 48 hours. The factors that affect the success rate of terbutaline administration in singleton pregnancy were cervical dilatation (ORs 0.37; 95%CI 0.18, 0.79) and cervical effacement (ORs 0.36; 95%CI 0.17, 0.75). The most common side effect of terbutaline was tachycardia (95.1%), but there were no serious cardiovascular events and maternal death. Mean neonatal birth weight was 2,294.3 + 638.4 grams. Neonatal complications included respiratory distress syndrome (RDS) 16.2%, intraventricular hemorrhage (IVH) 1.4%, necrotizing enterocolitis (NEC) 0.7%, sepsis 5.3%, and neonatal death 0.9%. The success rate of terbutaline in treatment of preterm labor was high while side effects were tolerable. Neonatal outcome was good. The factors that significantly affect the success rate of terbutaline administration in singleton pregnancy were cervical dilatation and cervical effacement. Thus, terbutaline can be used safely for short-term treatment of preterm labor.
    Journal of Maternal-Fetal and Neonatal Medicine 03/2015; DOI:10.3109/14767058.2015.1021671
  • [Show abstract] [Hide abstract]
    ABSTRACT: Preterm prelabor rupture of membranes (preterm PROM) accounts for 30-40% of spontaneous preterm deliveries and thus is a major contributor to perinatal morbidity and mortality. An amniotic fluid (AF) interleukin-6 (IL-6) concentration is a key cytokine for the identification of intra-amniotic inflammation, and patients at risk of impending preterm delivery, and adverse pregnancy complications. The conventional method to determine IL-6 concentrations in AF is an enzyme-linked immunosorbent assay (ELISA). However, this technique is not available in clinical settings and the results may take several days. A lateral flow-based immunoassay, or point of care (POC) test, has been developed to address this issue. The objective of this study was to compare the performance of AF IL-6 determined by the POC test to that determined by ELISA for the identification of intra-amniotic inflammation in patients with preterm PROM. This retrospective cohort study includes 56 women with singleton pregnancies who presented with preterm PROM. Amniocentesis was performed at the time of diagnosis and AF was analyzed using cultivation techniques for aerobic and anaerobic bacteria as well as genital mycoplasmas. AF Gram stain and AF white blood cell counts were determined. AF IL-6 concentrations were measured using both lateral flow-based immunoassay and ELISA. The primary outcome was intra-amniotic inflammation defined as AF ELISA IL-6 > 2,600 pg/ml. A previously determined cut-off of 745 pg/ml was used to define a positive POC test. 1) The POC test for AF IL-6 concentrations had 97% sensitivity and 96% specificity for the identification of intra-amniotic inflammation, as defined using ELISA among patients with preterm PROM; and 2) the diagnostic performance of the POC test for IL-6 was strongly correlated to that of an ELISA test for the identification of intra-amniotic inflammation and was equivalent for the identification of acute inflammatory placental lesions and MIAC. A point of care AF IL-6 test can identify intra-amniotic inflammation in patients with preterm PROM. Results can be available within 20 minutes - this makes it possible to implement interventions designed to treat intra-amniotic inflammation and improve pregnancy outcomes.
    Journal of Maternal-Fetal and Neonatal Medicine 03/2015; DOI:10.3109/14767058.2015.1006621